Promoter methylation and expression of TIMP3 gene in gastric cancer

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Guan, ZhiYu ^a   Zhang, Jun ^a   Song, ShiHui ^a   Dai, DongQiu ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Gastric Adenocarcinoma; Methylation; Tissue Inhibitor of Metalloproteinase 3 (TIMP3)

Indexed keywords

TIMP3 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CANCER STAGING; CHEMISTRY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGION; STOMACH TUMOR;

ADENOCARCINOMA; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR MARKERS, BIOLOGICAL;

EID: 84879825297     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-110     Document Type: Article

References (33)

1. Fang JY, Lu YY. Effects of histone acetylation and DNA methylation on p21(WAF1) regulation. World J Gastroenterol 2002, 8:400-405.
2. Kumar P, Xi Y. MicroRNA, epigenetic machinery and lung cancer. Thoracic Cancer 2011, 2:35-44.
3. Kimura N, Nagasaka T, Murakami J, Sasamoto H, Murakami M, Tanaka N, Matsubara N. Methylation profiles of genes utilizing newly developed CpG island methylation microarray on colorectal cancer patients. Nucleic Acids Res 2005, 33:e46. 10.1093/nar/gni046, 1064143, 15760842.
4. Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest 2004, 84:884-893. 10.1038/labinvest.3700108, 15122305.
5. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG island hyperme- thylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003, 163:1551-1556. 10.1016/S0002-9440(10)63511-0, 1868290, 14507661.
6. Oue N, Matsumura S, Nakayama H, Kitadai Y, Taniyama K, Matsusaki K, Yasui W. Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 2003, 64:423-429. 10.1159/000070302, 12759541.
7. Xue WC, Chan KY, Feng HC, Chiu PM, Ngan HY, Tsao SW, Cheung AN. Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma. Mol Diagn 2004, 6:326-334.
8. Kim H, Kim YH, Kim SE, Kim NG, Noh SH, Kim H. Concerted promoter hypermethy- lation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability. J Pathol 2003, 200:23-31. 10.1002/path.1325, 12692837.
9. Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, Ellison DW, Clifford SC. Identification of tumour-specific epigenetic events in medullo- blastoma development by hypermethylation profiling. Carcinogenesis 2004, 25:661-668.
10. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer Cancer 1997, 80(9):1803-1804.
11. Liu X, Xiong H, Li J, He Y, Yuan X. Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer. Diagn Pathol 2013, 8:62. 10.1186/1746-1596-8-62, 3674969, 23587030.
12. Dong X, Wang G, Zhang G, Ni Z, Suo J, Cui J, et al. The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer. Diagn Pathol 2013, 8:45. 10.1186/1746-1596-8-45, 3621381, 23510199.
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG island. Proc Natl Acad Sci USA 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
14. Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissue. Hum Pathol 1990, 21:607-612. 10.1016/S0046-8177(96)90006-4, 2161789.
15. Vogelauer M, Wu J, Suka N, Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000, 408:495-498. 10.1038/35044127, 11100734.
16. Sadiq A, Mansour KA. Esophageal cancer: recent advances. Thoracic Cancer 2011, 2:75-83.
17. Suter CM, Norrie M, Ku SL, Cheong KF, Tomlinson I, Ward RL. CpG island methylation is a common finding in colorectal cancer cell lines. Br J Cancer 2003, 88(3):413-419. 10.1038/sj.bjc.6600699, 2747532, 12569385.
18. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000, 16:168-174. 10.1016/S0168-9525(99)01971-X, 10729832.
19. Colot V, Maloisel L, Rossignol JL. DNA repeats and homologous recombination: a probable role for DNA methylation in genome stability of eukaryotic cells. J Soc Biol 1999, 193:29-34.
20. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancer. Cancer Res 2002, 62:6645-6650.
21. Leco KJ, Waterhouse P, Sanchez OH, Gowing KL, Poole AR, Wakeham A, Mak TW, Khokha R. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001, 108:817-829. 200926, 11560951.
22. Mannello F, Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001, 6:479-482. 10.1023/A:1012493808790, 11595838.
23. Smith MR, Kung H, Durum SK, Colburn NH, Sun Y. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 1997, 9:770-780. 10.1006/cyto.1997.0233, 9344510.
24. Gagnon J, Shaker S, Primeau M, Hurtubise A, Momparler RL. Interaction of 5-aza-2′- deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs 2003, 14:193-202. 10.1097/00001813-200303000-00002, 12634613.
25. Feng H, Cheung AN, Xue WC, Wang Y, Wang X, Fu S, Wang Q, Ngan HY, Tsao SW. Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma. Gynecol Oncol 2004, 94:375-382. 10.1016/j.ygyno.2004.04.019, 15297175.
26. Youn HG, An JY, Choi MG, Noh JH, Sohn TS, Kim S. Recurrence after curative resection of early gastric cancer. Ann Surg Oncol 2010, 17:448-454. 10.1245/s10434-009-0772-2, 19904573.
27. Jin J, Jin T, Quan M, Piao Y, Lin Z. Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Diagn Pathol 2012, 7:135. 10.1186/1746-1596-7-135, 3502371, 23039327.
28. Fan LL, Chen DF, Lan CH, Liu KY, Fang DC. Knockdown of ezrin via RNA interference suppresses Helicobacter pylori-enhanced invasion of gastric cancer cells. Cancer Biol Ther 2011, 11:746-752. 10.4161/cbt.11.8.14691, 21282970.
29. Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 1990, 55:87-131.
30. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004, 64:1975-1986. 10.1158/0008-5472.CAN-03-3972, 15026333.
31. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003, 163:1371-1378. 10.1016/S0002-9440(10)63495-5, 1868296, 14507645.
32. Galm O, Rountree MR, Bachman KE, Jair KW, Baylin SB, Herman JG. Enzymatic regional methylation assay:a novel method quantify regional CpG methylation densuty. Genome Res 2002, 12:153-157. 10.1101/gr.202501, 155259, 11779840.
33. Kang GH, Lee S, Shim YH, Kim JC, Ro JY, Shim Y-H. Profile of methylated CpG sites of hMLH1 promoter in primary gastric carcinoma with microsatellite instability. Cancer Res 2001, 61:2847-2851.